Test subscription


Test subscription

2cureX company profile

2cureX was founded in 2006 as a spin-out from the Carlsberg Research center in Copenhagen, with the vision of improving treatment efficiency for cancer patients. From its inception, 2cureX has been closely related to the major Cancer hospitals in the Nordics, Germany and The UK.

2cureX developed the IndiTreat® test; IndiTreat® matches the individual cancer patient with the most effective cancer treatment.

The IndiTreat® test for colorectal cancer has a European CE-IVD approval and the company is conducting ongoing multi-center clinical validation trials with leading Cancer hospitals within Ovarian Cancer and Pancreatic Cancer.

2cureX Headquarters is based in Copenhagen, Denmark, and the company’s shares are listed at Nasdaq First North in Stockholm (2CUREX.ST).

2cureX Business Model

2curex offers the IndiTreat test to cancer hospitals and oncology clinics. The testing method is based on a small tumor-sample from a patient that will be sent to a central 2cureX lab for analysis. The physician will receive a detailed drug-sensitivity report via Email after approximately 14 days upon delivery of the tissue sample to the 2cureX lab.

Subscription for 2cureX News and Press Releases

Language News type
Your information

Data storage policy

Contact information

2cureX, Fruebjergvej 3, 2100 Copenhagen Ø, Denmark| Phone: +45 2211 5399| E-mail: info@2curex.com

Privacy Policy | Imprint